Recursion Grants New RSUs Raising Questions On Dilution And Dividend Potential

Recursion Pharmaceuticals granted inducement RSU awards to 17 new employees under its 2024 Inducement Equity Incentive Plan. The awards are tied to recent hiring activity and are intended as ...

Recursion Pharmaceuticals股价触及52周低点3.53美元

Recursion Pharmaceuticals Inc .股价创下新的52周低点，收盘价为3.53美元，距离其52周绝对最低点3.54美元仅差几分钱。这一里程碑标志着该公司的重大下滑， InvestingPro 数据显示，过去一年该股价下跌了55.52%。根据InvestingPro的公允价值评估，该股票在当前水平略显低估。这家以通过机器学习和自动化进行创新药物发现而闻名的生物制药公司在市场上 ...

Assessing Recursion Pharmaceuticals (RXRX) After A 58% One-Year Share Price Decline

If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful starting point is understanding what the current market price might be ...

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...

Borgeson Blake以924,000美元出售Recursion Pharmaceuticals (RXRX)股票

根据提交给美国证券交易委员会的Form 4文件显示，董事Blake Borgeson于2026年2月3日出售了220,000股 Recursion Pharmaceuticals Inc (NASDAQ:RXRX) ...
腾讯网

英伟达推出生成式AI药物发现平台，与安进、Recursion达成合作

人工智能计算领导者英伟达（NVIDIA）在过去的一年里接连投资几家AI药物开发公司，其在药物开发领域的雄心壮志正在成为全世界的焦点。 日前，英伟达宣布了三项新举措，其中包括与安进（Amgen）子公司deCode进行新的合作。英伟达表示，deCode将利用英伟达的 ...
CNBC

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...
CNBC

Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
Nasdaq

Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

It's been a rough few years for investors excited about new biopharmaceutical companies that use artificial intelligence (AI) to select new drug candidates. Less than three years after raising $510 ...
Seeking Alpha

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...
Ars Technica

Recursion or while loops: Which is better?

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.